IDXX — IDEXX LABORATORIES INC /DE
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 874716 ·
Last close
$519.26
Market Cap
$40.91B
52W High
$769.98
52W Low
$500.61
ADV30
500,993
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 1,140,820,000 | 722,739,000 | 362,586,000 | 278,446,000 | 3,385,497,000 | 200,528,000 | 1,829,394,000 |
| Dec 2025 | 1,090,579,000 | 658,114,000 | 315,605,000 | 248,188,000 | 3,350,759,000 | 180,070,000 | 1,745,376,000 |
| Sep 2025 | 1,105,239,000 | 683,354,000 | 354,846,000 | 274,610,000 | 3,386,712,000 | 208,166,000 | 1,825,526,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,210,091,000
Investing CF
$-140,173,000
Financing CF
$-1,046,073,000
CapEx
$-141,984,000
Dividends Paid
—
Buybacks
$-1,167,110,000
EPS Diluted TTM
$14.22
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$6,670,348,000
Inventory
$382,400,000
Receivables
$697,212,000
ST Investments
—
EBIT TTM
$1,408,474,000
Pretax Income TTM
$1,369,547,000
Interest Exp TTM
$38,927,000
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,553,223,168
EBITDA
$1,621,684,992
Free Cash Flow
$909,368,384
Enterprise Value
$40,659,976,192
Total Cash
$196,932,992
Total Debt
$1,096,081,024
Shares Out
78,781,116
Trailing EPS
$14.23
Book Value
$20.45
ROE
74.2%
ROA
27.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,303,702,000 | 1,360,031,000 | 1,059,464,000 | 3,350,759,000 | 1,745,376,000 | 1,605,383,000 | 1,181,805,000 |
| Dec 2024 | 3,897,504,000 | 1,128,337,000 | 887,867,000 | 3,293,443,000 | 1,698,130,000 | 1,595,313,000 | 929,001,000 |
| Dec 2023 | 3,660,953,000 | 1,097,128,000 | 845,042,000 | 3,259,925,000 | 1,775,395,000 | 1,484,530,000 | 906,510,000 |
| Dec 2022 | 3,367,324,000 | 898,765,000 | 679,089,000 | 2,746,765,000 | 2,138,028,000 | 608,737,000 | 542,984,000 |
TTM Snapshot
Revenues TTM
$3,731,158,000
NetIncome TTM
$868,687,000
OpCashFlow TTM
$0
Assets (Latest)
$3,350,759,000
Forward EPS
$16.74
Max Pain — expiry 2026-10-16
max pain strike: $530.00 · spot: $525.07 · call oi: 791 · put oi: 468
Expected Move to 2026-10-16:
±$25.40
(4.84%) —
implied range
$499.67 –
$550.47
· ATM straddle on $530.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $44.50B | $270.37 | — |
| INCY | INCYTE CORP | $25.11B | $123.89 | — |
| MEDP | Medpace Holdings, Inc. | $17.27B | $618.88 | — |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $14.11B | $292.84 | — |
| ICLR | ICON PLC | $13.30B | $172.33 | — |
News headlines (Yahoo Finance, 1h cache)
Companion Animal Diagnostic Market Forecasts Growth from $3.56B (2026) to $5.40B by 2031, Profiling IDEXX Laboratories & Zoetis
2026-09-24 10:19 · Yahoo
Should You Continue to Hold IDXX Stock in Your Portfolio?
2026-09-23 12:53 · Yahoo
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets
2026-09-20 15:02 · Yahoo
IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics
2026-09-19 20:17 · Yahoo
IDEXX (IDXX) Stock Trades Below Fair Value Following Its 26% Slide
2026-09-18 03:15 · Yahoo
IDEXX Laboratories (IDXX) Could Be 29% Below Fair Value As Diagnostics Growth Stays In Focus
2026-09-17 22:16 · Yahoo
IDEXX Stock Gains Following the Acquisition of CoVet
2026-09-17 13:08 · Yahoo
Is IDEXX’s Expanded Zoonosis Testing Menu Altering The Investment Case For IDEXX Laboratories (IDXX)?
2026-09-17 11:11 · Yahoo
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
2026-09-17 07:00 · Yahoo
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
2026-09-16 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.